{"id":"NCT00542997","sponsor":"CSL Behring","briefTitle":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy","officialTitle":"A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2007-10-12","resultsPosted":"2011-03-15","lastUpdate":"2011-09-01"},"enrollment":51,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Common Variable Immunodeficiency","X-linked Agammaglobulinemia","Autosomal Recessive Agammaglobulinemia"],"interventions":[{"type":"BIOLOGICAL","name":"Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)","otherNames":["Hizentra","SCIG"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).","primaryOutcome":{"measure":"Total Serum IgG Trough Levels","timeFrame":"Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)","effectByArm":[{"arm":"IgPro20","deltaMin":8.1,"sd":1.44},{"arm":"Pre-study IgG Treatment","deltaMin":7.49,"sd":1.57}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":19,"countries":["France","Germany","Italy","Poland","Romania","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["21705277","21674136"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Bronchitis","Pyrexia","Cough","Headache","Nasopharyngitis"]}}